Massacheusetts biotech company is introducing a new dry powder delivery platform based on its iSPERSE cationic salt formulations at ISAM 2011. According to the company, the iSPERSE platform “enables inhaled delivery of high drug loads, large drug molecules, and multiple drug combinations.”
The formulations are produced by spray drying, using excipients that are generally recognized as safe (GRAS). The resulting powders are highly dispersible and do not require lactose carriers, according to Pulmatrix. The company is developing its own proprietary drugs and looking for partners.
Michael Lipp, VP of Development and Intellectual Property said, “Partners of our iSPERSE platform can harness the unique capabilities of iSPERSE to deliver single or combination drug formulations with a greater capacity to accommodate higher drug loadings than conventional inhaled technologies. From novel complex drug formulations to branded generics, Pulmatrix believes there are a number of significant opportunities to create inhaled drug products that meet clear and pressing market needs.”
Read the Pulmatrix press release.
